New insights into the regulation of TLR signaling

School of Biochemistry and Immunology, Trinity College Dublin, Dublin, Ireland.
Journal of Leukocyte Biology (Impact Factor: 4.29). 09/2006; 80(2):220-6. DOI: 10.1189/jlb.1105672
Source: PubMed


Toll-like receptor (TLR) activation is dictated by a number of factors including the ligand itself and the localization of the receptor, in terms of expression profile and subcellular localization and the signal transduction pathway that has been activated. Recent work into TLR signal transduction has revealed complex regulation at a number of different levels including regulation by phosphorylation, targeted degradation, and sequestration of signaling molecules. Here, we describe recent advances that have been made in our understanding of how TLR signaling is regulated at the biochemical level.

Download full-text


Available from: Sinead M Miggin,
  • Source
    • "TLR7 mediated production of both type I IFN and inflammatory cytokines requires MyD88 and indeed IRAK4 and TRAF6. Downstream, the signaling bifurcates wherein type I IFN secretion has a requirement for IRAK-1 while the IKK complex (IKKβ, γ) is required to drive NF-κB activation and concomitant proinflammatory cytokine production [37], [38]. Comparatively, limited studies have focused on understanding the dynamics of TLR7 mediated IFN signaling in macrophages. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Toll-like receptor 7 (TLR7) plays a vital role in the immune response to ssRNA viruses such as human rhinovirus (HRV) and Influenza, against which there are currently no treatments or vaccines with long term efficacy available. Clearly, a more comprehensive understanding of the TLR7 signaling axis will contribute to its molecular targeting. TRIF related adaptor molecule (TRAM) plays a vital role in TLR4 signaling by recruiting TRIF to TLR4, followed by endosomal trafficking of the complex and initiation of IRF3 dependent type I interferon production as well as NF-κB dependent pro-inflammatory cytokine production. Towards understanding the molecular mechanisms that regulate TLR7 functionality, we found that TRAM-/- murine macrophages exhibited a transcriptional and translational impairment in TLR7 mediated RANTES, but not TNFα, production. Suppression of TRAM expression in human macrophages also resulted in an impairment in TLR7 mediated CCL5 and IFN-β, but not TNFα, gene induction. Furthermore, suppression of endogenous human TRAM expression in human macrophages significantly impaired RV16 induced CCL5 and IFNβ, but not TNFα gene induction. Additionally, TRAM-G2A dose-dependently inhibited TLR7 mediated activation of CCL5, IFNβ and IFNα reporter genes. TLR7-mediated phosphorylation and nuclear translocation of IRF3 was impaired in TRAM-/- cells. Finally, co-immunoprecipitation studies indicated that TRAM physically interacts with MyD88 upon TLR7 stimulation, but not under basal conditions. Our results clearly demonstrate that TRAM plays a, hitherto unappreciated, role in TLR7 signaling through a novel signaling axis containing, but not limited to, MyD88, TRAM and IRF3 towards the activation of anti-viral immunity.
    PLoS ONE 09/2014; 9(9):e107141. DOI:10.1371/journal.pone.0107141 · 3.23 Impact Factor
  • Source
    • "Toll-like receptors (TLRs) are key regulators of the innate and adaptive immune responses, and are activated by specific pathogen-associated molecular patterns (1). The activation of TLRs initiates a signaling cascade and induces the expression of various important pro-inflammatory cytokines and finally leads to the eradication of infecting microbes (2). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Toll-like receptors (TLRs) play an essential role in the activation and regulation of the innate and adaptive immune responses through the recognition of specific components of pathogens. TLR1/2 on the cell surface plays an important role in defending against Gram-positive bacteria. The aim of the present study was to examine the expressional variation of immunomodulatory molecules in peripheral blood leukocytes (PBLs) treated with the TLR1/2 agonist, Pam3Cys. The quantitative polymerase chain reaction result showed dramatically increased expression of immune-related factors treated with Pam3Cys. Antibody-chip assays confirmed that activation of TLR1/2 could induce secretion of four important immune factors [interleukin (IL)-6, IL-8, macrophage inflammatory protein-1α and interferon-β). Western-blot analysis indicated the upregulation of three significant signal kinase proteins (phosphorylated signal transducer and activator of transcription 3, extracellular signal-related kinase and c-Jun N-terminal kinase 2). The study demonstrated that there were numerous molecules involved in the immune response of PBLs stimulated by the TLR1/2 ligand. Our future studies will focus on the mechanisms of these molecules in the TLR1/2 agonist-mediated immune response.
    Experimental and therapeutic medicine 06/2014; 7(6):1708-1712. DOI:10.3892/etm.2014.1621 · 1.27 Impact Factor
  • Source
    • "TLRs 1,2, and 6 hetero-dimerize and respond to lipopeptides; TLR3 binds double stranded RNAs; TLR4 signals when triggered by LPSs; TLR5 senses flagellins; TLR7 and 8 detect single stranded RNAs and TLR9 responds to DNA with CpG motifs [5,7-12]. To augment their ability to appropriately detect pathogens, the TLRs are partitioned where the likely source of the MAMP would be found; i.e. shed LPS is picked up by lipopolysaccharide binding protein and transported to the cell membrane where TLR4 is located and the viral RNA sensors TLR3, 7, and 8 are located in endosomes inside the cell where viral RNAs would be produced and their detection required [13,14]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Recent reports that TLR4 and TLR7 ligands can synergistically trigger Th1 biased immune responses suggest that an adjuvant that contains both ligands would be an excellent candidate for co-administration with vaccine antigens for which heavily Th1 biased responses are desired. Ligands of each of these TLRs generally have disparate biochemical properties, however, and straightforward co-formulation may represent an obstacle. We show here that the TLR7 ligand, imiquimod, and the TLR4 ligand, GLA, synergistically trigger responses in human whole blood. We combined these ligands in an anionic liposomal formulation where the TLR7 ligand is in the interior of the liposome and the TLR4 ligand intercalates into the lipid bilayer. The new liposomal formulations are stable for at least a year and have an attractive average particle size of around 140 nm allowing sterile filtration. The synergistic adjuvant biases away from Th2 responses, as seen by significantly reduced IL-5 and enhanced interferon gamma production upon antigen-specific stimulation of cells from immunized mice, than any of the liposomal formulations with only one TLR agonist. Qualitative alterations in antibody responses in mice demonstrate that the adjuvant enhances Th1 adaptive immune responses above any adjuvant containing only a single TLR ligand as well. We now have a manufacturable, synergistic TLR4/TLR7 adjuvant that is made with excipients and agonists that are pharmaceutically acceptable and will have a straightforward path into human clinical trials.
    Journal of Nanobiotechnology 04/2014; 12(1):17. DOI:10.1186/1477-3155-12-17 · 4.12 Impact Factor
Show more